Oryzon Genomics Overview

  • Founded
  • 2000
Founded
  • Status
  • Public
  • Employees
  • 43
Employees
  • Stock Symbol
  • ORY
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $4.63
  • (As of Tuesday Closing)

Oryzon Genomics General Information

Description

Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.

Contact Information

Website
www.oryzon.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Stock Exchange
XMAD
Primary Office
  • Sant Ferran 74
  • Cornellà de Llobregat
  • 08940 Barcelona
  • Spain
+34 935 00 00 00

Oryzon Genomics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Oryzon Genomics Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.63 $4.60 $2.93 - $5.37 $244M 52.8M 188K -$0.10

Oryzon Genomics Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 186,066 187,910 108,059 86,437
Revenue 0 0 0
EBITDA (5,643) (4,747) (4,109) (3,263)
Net Income (4,736) (3,875) (4,125) (1,389)
Total Assets 111,852 115,748 89,720 77,157
Total Debt 13,639 11,183 10,615 16,961
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Oryzon Genomics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Oryzon Genomics‘s full profile, request access.

Request a free trial

Oryzon Genomics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based the
Biotechnology
Barcelona, Spain
43 As of 2020
00000
000000000 00000

00000 00

re et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi u
0000000000000
Pittsburgh, PA
0 As of 0000
00.000
0000000000 0 00.000

0000000

boris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate v
0000000000000
Brisbane, CA
000 As of 0000
000.00
00000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Oryzon Genomics Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sharp Edge Labs Venture Capital-Backed Pittsburgh, PA 0 00.000 0000000000 0 00.000
0000000 0000000000 Formerly VC-backed Brisbane, CA 000 000.00 00000000 000.00
0000000 0000000000 Venture Capital-Backed Nijmegen, Netherlands 00 000.00 00000000000 000.00
00000 000000000000 Formerly VC-backed Leiden, Netherlands 000 00000 000000 - 000 00000
00000000 000000000 Formerly Accelerator/Incubator backed San Diego, CA 000 000.00 000000000 000.00
You’re viewing 5 of 9 competitors. Get the full list »

Oryzon Genomics Executive Team (17)

Name Title Board Seat Contact Info
Carlos Buesa Ph.D Co-Founder, Chief Executive Officer & Chairman
Enric Rello Chief Operating Officer & Chief Financial Officer, Spain
Torsten Hoffmann Chief Scientific Officer
Emili Torrell Chief Business Development Officer
Neus Virgili Chief Intellectual Property Officer
You’re viewing 5 of 17 executive team members. Get the full list »

Oryzon Genomics Board Members (9)

Name Representing Role Since
Carlos Buesa Ph.D Oryzon Genomics Co-Founder, Chief Executive Officer & Chairman 000 0000
Isabel Navarro Oryzon Genomics Board Member 000 0000
You’re viewing 2 of 9 board members. Get the full list »

Oryzon Genomics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oryzon Genomics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 0000000000 27-Jan-2009 000000000000000000 Biotechnology 000000 00000 00.0
To view Oryzon Genomics’s complete acquisitions history, request access »